Opera Trading Capital’s Novavax NVAX Stock Holding History

Opera Trading Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-710	Closed	-$27K	–	140
2018 Q3	$27K	Buy	+710	New	+$20K	0.01%	156

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Opera Trading Capital's NVAX Position: Q4 2018 in Review

Opera Trading Capital sold out of Novavax (NVAX) in Q4 2018, closing a stake of 710 shares — an estimated $27K sold.

Opera Trading Capital first reported a position in NVAX in Q3 2018 and held it in 1 quarter. The position peaked at $27K in Q3 2018. 167 funds tracked by Wall St. Rank hold NVAX as of Q4 2018.

Opera Trading Capital reported no remaining Novavax position as of Q4 2018 after selling out during the quarter.
Opera Trading Capital sold 710 Novavax shares in Q4 2018, an estimated $27K.
Opera Trading Capital first reported a position in Novavax in Q3 2018 and held it in 1 quarter.
Opera Trading Capital's Novavax position peaked at $27K in Q3 2018.
167 funds tracked by Wall St. Rank held Novavax as of Q4 2018.

Based on Opera Trading Capital's 13F filing for Q4 2018, filed 22 Jan 2019.